<Abstract of published report>Carbonic Anhydrase III in Serum in Muscular Dystropy and Other Neurological Disorders : Relationship with Creatine Kinase.
スポンサーリンク
概要
著者
-
Okita Mika
Department Of Molecular Gastroenterology & Hepatology Kyoto Prefectural University Graduate Scho
-
Ohta Mitsuhiro
Department Of Medical Biochemistry Kobe Pharmaceutical University
関連論文
- Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts
- The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis : A prospective, multicenter study
- Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C : a Japanese multi-center study
- Amyloidosis localized in the sigmoid colon
- Elevation of serum thioredoxin levels in patients with nonalcoholic steatohepatitis
- Carbonic Anhydrase III in Serum in Muscular Dystropy and Other Neurological Disorders : Relationship with Creatine Kinase.
- Detection and Characterization of Blocking-Type Anti-Acetylcholine Receptor Antibodies in Sera from Patients with Myasthenia Gravis.
- Nicotinic Acetylcholine Receptor mRNAs in Myasthenic Thymuses : Association with Intrathymic Pathogenesis of Myasthenia Gravis.
- Immunological Detection of the Dystrophin Molecule with Antibody Directed Against the Synthetic Peptide.
- Anti-skeletal Muscle and Anti-acetylcholine Receptor Antibodies in Patients with Thymoma without Myasthenia gravis : Relation to the Onset of Myasthenia gravis.
- Carbonic Anhydrase III in Serum in Muscular Dystrophy and Other Neurological Disorders : Relationship with Creatine Kinase.
- Improved Radioassay of Anti-acetylcholine Receptor Antibody : : Application for the Detection of Extremely Low Antibody Titers In Sera from Patients with Myasthenia Gravis.
- Antibodies to Synthetic Peptide (125-148) of the α-Subunit of Human Nicotinic Acetylcholine Receptor in Sera from Patients with Myasthenia Gravis.
- Anti-skeletal Muscle Antibodies in the Sera from Myasthenic Patients with Thymoma : Identification of Anti-Myosin, Actomyosin, Actin, and α-Actinin Antibodies by a Solid-phase Radioimmunoassay and a Western Blotting Analysis.
- First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C
- Hepatic senescence marker protein-30 is involved in the progression of nonalcoholic fatty liver disease
- HLA-Associated Cellular Response to GAD in Type 2 Diabetes with Antibodies to GAD
- Isolation of Two Novel Alternative Splicing Variants of Allograft Inflammatory Factor-1.
- Enzyme Immunoassay for Measuring Antibodies against Skeletal Muscle in Patients with Myasthenia Gravis.
- Human Artial Natriuretic Peptide in the Plasma from Patients with Duchenne Muscular Dystrophy.
- Patients with Myasthenia Gravis and Thymoma Have Anti-Skeletal Muscle and Anti-Acetylcholine Receptor Antibodies Simultaneously.
- Solid-Phase Radioimmunoassay for Antibody to Myelin Basic Protein and Its Measurement in Sera from Patients with Neurological Diseases.
- Anti-Acetylcholine Receptor Antibody in Myasthenia Gravis : Relationship to Disease Severity and Effect of Thymectomy.
- Primary Structure of α-Bungarotoxin : Six Amino Acino Residues Differ from the Previously Reported Sequence.
- Anti-Striaitional Muscle Antibodies in Myasthenia Gravis : Especially in Myasthenia Gravis with Thymoma
- Serum Carbonic Anhydrase III in Patients with Neuromuscular Disorders.
- Determination of Serum Carbonic Anhydrase III in Muscular Disorders and Its Clinical Significance.
- Serum Concentrations of Δ5-3β-Hydroxysteroids in Type 2 Diabetes Mellitus
- Enzyme-linked immunosorbent assay of nicotine metabolites
- GENERAL RULES FOR RECORDING ENDOSCOPIC FINDINGS OF ESOPHAGOGASTRIC VARICES (2ND EDITION)
- Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease
- Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes